Does COVID‐19 count?: Defining Criterion A trauma for diagnosing PTSD during a global crisis Wiley
Under Pressure: How Social Media, Drugs, and the Changing Landscape of Sexuality Are Challenging Younger Generations' Mental Health Everyday Health
Would You Recommend Skydiving at the Age 100? Formulating Risk Decisions Psychiatric Times
Internal emails reveal questions, confusion on Trump religious freedom directive Washington Blade
Janssen Announces US FDA Approval of INVEGA HAFYERA™ (6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia | Small Molecules | News Channels PipelineReview.com
FDA clears J&J's twice-yearly Invega for schizophrenia - pharmaphorum
The Double-Edged Sword Of App Engagement And Gambling Addiction OnlinePokerReport.com
FDA Approves First Twice-Yearly Antipsychotic for Schizophrenia Medscape
